Source - LSE Regulatory
RNS Number : 2278G
Argent Biopharma Limited
30 September 2024
 

 

30 September 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Annual Report for the year ended 30 June 2024

and ASX Corporate Governance Statement

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector is pleased to provide the following documents in respect of the financial year ended 30 June 2024:

 

·    Annual Financial Report (Audited)

A copy of the Company's Annual Financial Report for the year ended 30 June 2024 can be found at the following URL:

https://www.investi.com.au/api/announcements/rgt/f19a9293-4b8.pdf

 

·    ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and Argent BioPharma's Corporate Governance Statement

A copy of the Company's ASX Appendix 4G - Corporate Governance Disclosures & Corporate Governance Statement can be found at the following URL:

https://www.investi.com.au/api/announcements/rgt/81d037ff-a07.pdf

 

-Ends-

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSVBLBXZKLXBBF
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Argent Biopharma Limited (RGT)

-0.35p (-2.19%)
delayed 16:57PM